Linking the Provider Recommendation to Adolescent HPV Vaccine Uptake

Date: Thursday November 21, 2019
Time: 1:00 – 2:00 pm EST

PAR-19-360 (R01)External Web Site Policy; PAR-19-359 (R03)External Web Site Policy; PAR-19-358 (R21)External Web Site Policy

Webinar Materials

video icon Watch WebinarExternal Web Site Policy
PDF icon View Presentation (PDF, 339 KB)
PDF icon View FAQs (PDF, 116 KB)


The National Cancer Institute has re-issued the notice of funding opportunity (NOFO) Linking the Provider Recommendation to Adolescent HPV Vaccine Uptake (Clinical Trial Optional) (PAR-19-360External Web Site Policy [R01]; PAR-19-359External Web Site Policy [R03] and PAR-19-358External Web Site Policy [R21]). This NOFO encourages research on how the health care delivery system enhances or inhibits the effectiveness of a provider's recommendation of the adolescent human papillomavirus (HPV) vaccine. Characteristics of the provider, parent/patient, and clinical setting can all affect whether a provider makes a recommendation, and whether that recommendation results in uptake of the HPV vaccine. This research requires expertise in cancer prevention, adult and childhood behavior, immunization promotion, and health care delivery.

Intended Audience

Extramural investigators at junior, mid-, and senior levels.


Sarah Kobrin

Sarah Kobrin, PhD, MPH
Chief, Health Systems and Interventions Research Branch
Healthcare Delivery Research Program
Division of Cancer Control and Population Sciences

This webinar will be archived on the HDRP Events webpage.

Last Updated: 19 Apr, 2024